|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the ABII 10-K filed Mar 6, 2009. Exclusive License of Intellectual Property Portfolio In May 2007, we entered into an agreement with the University of Southern California (USC) that provides us with the exclusive worldwide development and commercialization rights for an intellectual property portfolio of diagnostic protein biomarkers for therapy response, therapy toxicity and disease recurrence in colorectal cancers (CRCs). Exclusive License of In May 2007, we entered into an agreement with the University of Southern California (USC) that This excerpt taken from the ABII 10-K filed Mar 31, 2008. Exclusive License of Intellectual Property Portfolio In May 2007, we entered into an agreement with the University of Southern California (USC) that provides us with the exclusive worldwide development and commercialization rights for an intellectual property portfolio of diagnostic protein biomarkers for therapy response, therapy toxicity and disease recurrence in colorectal cancers (CRCs). This excerpt taken from the ABII 10-Q filed Dec 20, 2007. Exclusive License of Intellectual Property Portfolio In May 2007, we entered into an agreement with the University of Southern California (USC) that provides us with the exclusive worldwide development and commercialization rights for an intellectual property portfolio of diagnostic protein biomarkers for therapy response, therapy toxicity and disease recurrence in colorectal cancers (CRCs).
7
Table of ContentsThis excerpt taken from the ABII 8-K filed Nov 8, 2007. Exclusive License of Intellectual Property Portfolio In May 2007, New Abraxis entered into an agreement with the University of Southern California (USC) under which it was licensed with the exclusive worldwide development and commercialization rights for an intellectual property portfolio of diagnostic protein biomarkers for therapy response, therapy toxicity and disease recurrence in colorectal cancers (CRCs). The intellectual property licensed is based on USC research by Associate Professor of Medicine Heinz-Joseph Lenz and colleagues. | EXCERPTS ON THIS PAGE:
|
| |||||||
